【摘要】 目的  探讨替米沙坦联合瑞舒伐他汀对T2DM合并冠心病患者血清肝细胞生长因子(HGF)及其受体(c-met)和PPAR-γ表达水平的影响。 方法  选择95例T2DM合并冠心病患者,将其分为对照组、替米沙坦组和替米沙坦联合瑞舒伐他汀组。检测各组血清HGF、c-met和PPAR-γ水平。 结果  与对照组比较，替米沙坦组、替米沙坦联合瑞舒伐他汀组治疗后HGF [(338.96±36.51) vs (241.56±29.88) vs (173.23±32.25)  pg/ml]、c-met [(0.657±0.162) vs (0.489±0.093)  vs (0.247± 0.075) ng/ml] 和PPAR-γ[(53.76±11.97) vs (35.12±9.66) vs (23.91±6.87)vs  pg/ml] 水平降低（P＜0.05），且替米沙坦联合瑞舒伐他汀组上述指标较替米沙坦组下降更明显（P<0.05)。 结论  替米沙坦与他汀类药物联合应用有可能改善T2DM合并冠心病患者血管的内皮损伤，为临床防治糖尿病早期冠状动脉粥样硬化提供了新的思路。

【关键词】肝细胞生长因子；糖尿病，2型；冠心病；替米沙坦；瑞舒伐他汀

The effect of Telmisartan and Rosuvastatin on hepatocyte growth factor and peroxisome proliferator activated receptor γ in T2DM patients with coronary heart disease LIU Hui，LI Hai-jian，GAO Chuan-yu，et al. Department of Special Needs， Nanyang Central Hospital， Nanyang 473009,China

Corresponding author:GAO Chuan-yu,E-mail:gaocylhj@163.com

【Abstract】 Objective  To investigate the effect of Telmisartan and Rosuvastatin on hepatocyte growth factor（HGF）, HGF receptor [mesenchymal-epithelial transition factor(c-met)] and peroxisome proliferator activated receptor γ(PPARγ) in T2DM patients with coronary heart disease.  Methods  A total of 95 T2DM patients with coronary heart disease were enrolled in this study and divided into three groups: control group, Telmisartan treatment group, and Telmisartan and Rosuvastatin treatment group. Serum HGF,c-met,PPAR-γwere measured in all the patients. Results The levels of HGF, c-met, and PPAR-γexpression were significantly lower in Telmisartan treatment group and Telmisartan and Rosuvastatin treatment group than in control group, HGF[(241.56±29.88)vs(173.23±32.25) vs (338.96±36.51) pg/ml, P<0.05], c-met [(0.489±0.093)vs(0.247± 0.075)vs (0.657±0.162)ng/ml, P<0.05] and PPAR-γ[(35.12±9.66)vs(23.91±6.87)vs (53.76±11.97) pg/ml,P<0.05] respectively. HGF, c-met and PPAR-γ were lowest in Telmisartan and Rosuvastatin treatment group (P<0.05).  Conclusion Telmisartan combined with Rosuvastatin probably has a synergistic effect on prevention and treatment of diabetic vascular endothelial injury. This may be a new way in prevention of coronary atherosclerosis in T2DM patients.

【Key words】Hepatocyte growth factor(HGF); Diabetes mellitus,type 2; Coronary heart disease(CHD); Telmisartan; Rosuvastatin